Storage Stability
Beta-CGRP (CGRP-II) is a 37-amino-acid neuropeptide encoded by the CALCB gene, the paralog of the CALCA gene that produces alpha-CGRP. The two isoforms differ at positions 3, 22, and 25 of their sequence (87% homology) and have nearly identical pharmacological profiles at CGRP receptors (CLR/RAMP1). Beta-CGRP is more abundant than alpha-CGRP in the gut and thyroid, while alpha-CGRP predominates in sensory neurons.
Mechanism of Action
- Binds CLR/RAMP1 receptor complex identically to alpha-CGRP; activates Gs/cAMP/PKA and beta-arrestin pathways with equivalent potency
- Potent vasodilatory: CLR/RAMP1 on vascular smooth muscle and endothelium drives cAMP-mediated relaxation of arterioles
- Trigeminal pain modulation: beta-CGRP release from trigeminovascular neurons contributes to neurogenic inflammation and migraine
- GI motility: enteric beta-CGRP inhibits gastric acid secretion and modulates intestinal peristalsis via sensory neuron-to-smooth muscle signaling
- Bone: promotes osteoblast differentiation and inhibits osteoclast activity via CLR/RAMP1 in bone cells
Research Findings
- Beta-CGRP and alpha-CGRP have equivalent vasodilatory potency in human forearm blood flow infusion studies
- CGRP receptor antagonists (gepants: rimegepant, ubrogepant) block both alpha and beta-CGRP with equal potency, confirming shared receptor
- Anti-CGRP monoclonal antibodies (erenumab, fremanezumab) bind the peptide (alpha- and/or beta-CGRP) or receptor for migraine prevention
- Beta-CGRP plasma levels elevated during migraine attacks alongside alpha-CGRP, contributing to neurogenic vasodilation
- Thyroid-derived beta-CGRP may play local role in calcitonin-producing cell (C-cell) regulation and bone metabolism
Research Protocols
- Vasodilation: IV infusion of 2-8 pmol/min beta-CGRP in forearm brachial artery; measure blood flow by plethysmography (same protocol as alpha-CGRP)
- CGRP receptor binding: 125I-beta-CGRP vs unlabeled competitor; Kd ~0.1-0.3 nM at CLR/RAMP1
- Migraine model (rodent): 1 nmol intracisternal beta-CGRP produces facial allodynia and freezing; reversed by gepant
- In vitro osteoblast: 1-100 nM beta-CGRP in MC3T3-E1 cultures; measure ALP and osteocalcin vs alpha-CGRP
Interactions
- Alpha-CGRP: pharmacologically equivalent partner; most CGRP biology attributable to combined alpha + beta release from sensory and thyroid neurons
- Erenumab (AMG-334): anti-CLR/RAMP1 receptor antibody; blocks both alpha- and beta-CGRP signaling
- Rimegepant/ubrogepant (gepants): small-molecule CLR/RAMP1 antagonists; block beta-CGRP with same IC50 as alpha-CGRP
Safety Profile
Endogenous neuropeptide; identical safety considerations to alpha-CGRP. Anti-CGRP therapies blocking both isoforms approved for migraine prevention (erenumab, fremanezumab) with excellent safety record. Theoretical concern of CGRP blockade on cardiac and wound healing vasodilation not substantiated in clinical trials.
Legal & Regulatory
Endogenous neuropeptide; not an approved therapeutic itself. Anti-CGRP pathway drugs (gepants, mAbs) are FDA-approved for migraine.
Ready to dose Beta-CGRP?
Get the exact syringe draw
You have read the research. Now run the math. Pick your vial size and BAC water volume, get IU draw in seconds.
Open the Calculator →
More in Cognitive & Mood
View all →